Cargando…
Stem cell-based therapy for human diseases
Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in r...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357075/ https://www.ncbi.nlm.nih.gov/pubmed/35933430 http://dx.doi.org/10.1038/s41392-022-01134-4 |
_version_ | 1784763660516720640 |
---|---|
author | Hoang, Duc M. Pham, Phuong T. Bach, Trung Q. Ngo, Anh T. L. Nguyen, Quyen T. Phan, Trang T. K. Nguyen, Giang H. Le, Phuong T. T. Hoang, Van T. Forsyth, Nicholas R. Heke, Michael Nguyen, Liem Thanh |
author_facet | Hoang, Duc M. Pham, Phuong T. Bach, Trung Q. Ngo, Anh T. L. Nguyen, Quyen T. Phan, Trang T. K. Nguyen, Giang H. Le, Phuong T. T. Hoang, Van T. Forsyth, Nicholas R. Heke, Michael Nguyen, Liem Thanh |
author_sort | Hoang, Duc M. |
collection | PubMed |
description | Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment. |
format | Online Article Text |
id | pubmed-9357075 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93570752022-08-08 Stem cell-based therapy for human diseases Hoang, Duc M. Pham, Phuong T. Bach, Trung Q. Ngo, Anh T. L. Nguyen, Quyen T. Phan, Trang T. K. Nguyen, Giang H. Le, Phuong T. T. Hoang, Van T. Forsyth, Nicholas R. Heke, Michael Nguyen, Liem Thanh Signal Transduct Target Ther Review Article Recent advancements in stem cell technology open a new door for patients suffering from diseases and disorders that have yet to be treated. Stem cell-based therapy, including human pluripotent stem cells (hPSCs) and multipotent mesenchymal stem cells (MSCs), has recently emerged as a key player in regenerative medicine. hPSCs are defined as self-renewable cell types conferring the ability to differentiate into various cellular phenotypes of the human body, including three germ layers. MSCs are multipotent progenitor cells possessing self-renewal ability (limited in vitro) and differentiation potential into mesenchymal lineages, according to the International Society for Cell and Gene Therapy (ISCT). This review provides an update on recent clinical applications using either hPSCs or MSCs derived from bone marrow (BM), adipose tissue (AT), or the umbilical cord (UC) for the treatment of human diseases, including neurological disorders, pulmonary dysfunctions, metabolic/endocrine-related diseases, reproductive disorders, skin burns, and cardiovascular conditions. Moreover, we discuss our own clinical trial experiences on targeted therapies using MSCs in a clinical setting, and we propose and discuss the MSC tissue origin concept and how MSC origin may contribute to the role of MSCs in downstream applications, with the ultimate objective of facilitating translational research in regenerative medicine into clinical applications. The mechanisms discussed here support the proposed hypothesis that BM-MSCs are potentially good candidates for brain and spinal cord injury treatment, AT-MSCs are potentially good candidates for reproductive disorder treatment and skin regeneration, and UC-MSCs are potentially good candidates for pulmonary disease and acute respiratory distress syndrome treatment. Nature Publishing Group UK 2022-08-06 /pmc/articles/PMC9357075/ /pubmed/35933430 http://dx.doi.org/10.1038/s41392-022-01134-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Article Hoang, Duc M. Pham, Phuong T. Bach, Trung Q. Ngo, Anh T. L. Nguyen, Quyen T. Phan, Trang T. K. Nguyen, Giang H. Le, Phuong T. T. Hoang, Van T. Forsyth, Nicholas R. Heke, Michael Nguyen, Liem Thanh Stem cell-based therapy for human diseases |
title | Stem cell-based therapy for human diseases |
title_full | Stem cell-based therapy for human diseases |
title_fullStr | Stem cell-based therapy for human diseases |
title_full_unstemmed | Stem cell-based therapy for human diseases |
title_short | Stem cell-based therapy for human diseases |
title_sort | stem cell-based therapy for human diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357075/ https://www.ncbi.nlm.nih.gov/pubmed/35933430 http://dx.doi.org/10.1038/s41392-022-01134-4 |
work_keys_str_mv | AT hoangducm stemcellbasedtherapyforhumandiseases AT phamphuongt stemcellbasedtherapyforhumandiseases AT bachtrungq stemcellbasedtherapyforhumandiseases AT ngoanhtl stemcellbasedtherapyforhumandiseases AT nguyenquyent stemcellbasedtherapyforhumandiseases AT phantrangtk stemcellbasedtherapyforhumandiseases AT nguyengiangh stemcellbasedtherapyforhumandiseases AT lephuongtt stemcellbasedtherapyforhumandiseases AT hoangvant stemcellbasedtherapyforhumandiseases AT forsythnicholasr stemcellbasedtherapyforhumandiseases AT hekemichael stemcellbasedtherapyforhumandiseases AT nguyenliemthanh stemcellbasedtherapyforhumandiseases |